EuroBiotech: More Articles of Note


> HaYa Therapeutics and GNUbiotics became the first companies to join the Swiss Biopole startup incubator. The startups will move into the facility when it opens in the spring of 2018, becoming the first of the 10 to 12 companies Biopole expects to host at any one time. Statement (PDF)

> Carrick Therapeutics dosed the first patient in a phase 1 trial of its cyclin-dependent Kinase 7 selective inhibitor. The cancer candidate is expected to move into an efficacy trial next year. Release

> Gene therapy startup Orchard Therapeutics expanded its technical operations in California. The expansion quadruples the U.K. biotech’s technical operations laboratory footprint. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Symphogen pocketed a $5 million (€4 million) milestone after Roche’s Genentech moved a Staphylococcus aureus candidate into phase 1b. Release

> Analysts talked up the prospect of Johnson & Johnson buying Genmab. Reuters 

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.